Study to Assess the Effect of Zinc in Atorvastatin Treated Hyperlipidemic Patients

• Status: Recruiting
• Trial end date: 2022-07-10
• Target enrollment: 0
• Participant gender: All

Summary

This study was 8 weeks randomized, double-blind, placebo-controlled trial to assess the effect of zinc in Atorvastatin treated hyperlipidemic 92 patients. Participants were assessed at baseline, and 8 weeks. Subjects were randomized to receive either atorvastatin+placebo in one arm or atorvastatin +zinc 30mg tablet in another arm daily for 8 weeks. The outcome was the measure of fasting lipid profile, sgpt, serum creatinine at baseline and after 8 weeks following the intervention.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
• Treatments: Zinc Sulfate

Criteria

Inclusion Criteria:

• Age: 18 to 75 years

• Sex: both male and female

• Hyperlipidemic patients suffering from ischemic heart disease, diabetes mellitus, hypertension.

• A person can develop hyperlipidemia if they have one or a combination of the following: Diagnostic criteria for dyslipidemic patients (NCEP ATP III guideline) Total Cholesterol > 240 mg/dl LDL-C > 100 mg/dl Triglyceride > 150 mg/dl HDL-C < 40 mg/dl

Exclusion Criteria:

• Patients with renal impairment.

• Patient with history of active liver disease (e.g. jaundice, hepatitis, cirrhosis)

• Patients having hypersensitivity to drugs.

• Patients with any systemic diseases or having serious infections or terminal illness (e.g.-tuberculosis, HIV, malignant tumor)

• Pregnant woman

• lactating mother